HIV Prevention Review Meeting 2022

Welcome

In 2020, 1.5 million new HIV cases were reported worldwide. To end the HIV epidemic, effective prevention strategies are critical. The efficacy and effectiveness of the first approved PrEP regimens at the individual and population levels have fueled further research, and we are currently in the midst of a new exciting chapter. The diversity in new drugs and their formulations, including long-acting injectables, implants, and vaginal rings highlights a sustained educational need. Real-world data suggest different challenges in PrEP implementation, such as the perception of risk, compromised adherence, costs, availability, and structural barriers. Implementation challenges reflect regional differences in healthcare settings indicating a need for tailored educational programs to discuss best practices and better align guidelines and policies inclusive to all at-risk groups.

The HIV Prevention Series is designed to promote understanding among physicians, nurses, policymakers, and community advocates on antiretroviral drugs for prevention, novel formulations, and devices. It also includes implementation strategies and individual and community-based behavioral aspects of prevention as well as insights into the vaccine landscape and prospects of monoclonal antibodies for HIV prevention.

The HIV Prevention Review Meeting 2022 provided an overview of scientific advances, the importance of these findings, and their implications for the implementation of prevention programs.

This will be followed by the Asia-Pacific regional program, that will focus on regional guidelines, barriers to PrEP access, and strategies to overcome those.

General Information

Practical Information 

We trust that the following information (in alphabetical order) will assist you in organising your participation in the HIV Prevention Review Program 2022.